New Uses for Older Antibiotics: Nitrofurantoin, Amikacin, Colistin, Polymyxin B, Doxycycline, and Minocycline Revisited

Medical Clinics of North America

Volumn 90, Issue 6, 2006, Pages 1089-1107

  Cunha, Burke A ^a,b  

^a STONY BROOK UNIVERSITY   (United States)

^b WINTHROP UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; COLISTIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DOXYCYCLINE; GENTAMICIN; LINEZOLID; MACROLIDE; MEROPENEM; MINOCYCLINE; NAFCILLIN; NITROFURANTOIN; OXACILLIN; PENICILLIN DERIVATIVE; POLYMYXIN B; QUINOLONE DERIVATIVE; RIFAMPICIN; TETRACYCLINE; TIGECYCLINE; TOBRAMYCIN; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; BACTERIAL COLONIZATION; BACTERIAL INFECTION; BACTERIURIA; BARTONELLA; BURKHOLDERIA; CHLAMYDOPHILA PNEUMONIAE; CHLAMYDOPHILA PSITTACI; COXIELLA BURNETII; CYSTITIS; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; ENDOCARDITIS; ENTEROBACTER; ENTEROCOCCUS; ENTEROCOCCUS FAECIUM; FRANCISELLA TULARENSIS; GASTROINTESTINAL SYMPTOM; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; HUMAN; INTESTINE LIPODYSTROPHY; KLEBSIELLA PNEUMONIAE; LEGIONELLA; LYME DISEASE; MALARIA FALCIPARUM; MELIOIDOSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORAXELLA CATARRHALIS; MYCOBACTERIUM TUBERCULOSIS; MYCOPLASMA; NEPHROTOXICITY; NOCARDIA; NONHUMAN; OTOTOXICITY; PATHOGENESIS; PENICILLIN RESISTANCE; PNEUMONIA; PRIORITY JOURNAL; PROTEUS; PSEUDOMONAS AERUGINOSA; REVIEW; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; UNSPECIFIED SIDE EFFECT; VIBRIO CHOLERAE; ZOONOSIS;

AMIKACIN; CELL MEMBRANE; COLISTIN; DOXYCYCLINE; DRUG RESISTANCE, MICROBIAL; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; METHICILLIN RESISTANCE; MINOCYCLINE; NITROFURANTOIN; POLYMYXIN B; STAPHYLOCOCCAL INFECTIONS; URINARY TRACT INFECTIONS;

EID: 33750969982     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2006.07.006     Document Type: Review

References (104)

1. In: Kucers A., Crowe S.M., Grayson M.L., et al. (Eds). The use of antibiotics. A clinical review of antibacterial, antifungal and antiviral drugs. 5th edition (1997), Butterworth Heinemann, Oxford (UK) 676-708
2. In: O'Grady F., Lambert H.P., Finch R.G., et al. (Eds). Antibiotics and chemotherapy. 2nd edition (1997), Churchill Livingstone, New York
3. In: Bryskier A. (Ed). Antimicrobial agents (2005), ASM Press, Washington, DC
4. Cunha B.A. New uses for older antibiotics. Postgrad Med 101 (1997) 68-80
5. Klein N.C., and Cunha B.A. New uses for older antibiotics. Med Clin North Am 85 (2001) 125-132
6. Cunha B.A. Clinical relevance of penicillin-resistant Streptococcus pneumoniae. Semin Respir Infect 17 (2002) 204-214
7. Linden P.K. Treatment options for vancomycin-resistant enterococcal infections. Drugs 62 (2002) 425-441
8. Cunha B.A. Intravenous to oral antibiotic switch therapy. Drugs for Today 37 (2001) 311-319
9. Edson R.S., and Terrel C.L. The aminoglycosides. Mayo Clin Proc 74 (1999) 519-528
10. Cunha B.A. Aminoglycosides: current role in antimicrobial therapy. Pharmacotherapy 8 (1988) 334-350
11. Nicolle L.E. Urinary tract infection: traditional pharmacologic therapies. Am J Med Suppl 1A (2002) 35S-44S
12. In: Kucers A., Crowe S.M., Grayson M.L., et al. (Eds). The use of antibiotics. A clinical review of antibacterial, antifungal and antiviral drugs. 5th edition (1997), Butterworth-Heinemann, Oxford (UK) 922-931
13. Jain R., and Danziger L.H. Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians. Ann Pharmacother 38 (2004) 1449-1459
14. Evans M.E., Feola D.J., and Rapp R.P. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother 33 (1999) 960-967
15. In: Cunha B.A. (Ed). Antibiotic essentials. 5th edition (2006), Physicians' Press, Royal Oak (MI)
16. In: Ambrose P., and Nightingale C.H. (Eds). Principles of pharmacodynamics (2001), Marcel Dekker, New York
17. Cunha B.A. Nitrofurantoin: a review. Adv Ther 6 (1989) 213-236
18. Gordon K.A., and Jones R.N. Susceptibility patterns of orally administered antimicrobials among urinary tract infection pathogens from hospitalized patients in North America: comparison report to Europe and Latin America. Results from the SENTRY Antimicrobial Surveillance Program (2000). Diagn Microbiol Infect Dis 45 (2003) 295-301
19. Zhanel G.G., Laing N.M., Nichol K.A., et al. Antibiotic activity against urinary tract infection (UTI) isolates of vancomycin-resistant enterococci (VRE): results from the 2002 North American Vancomycin Resistant Enterococci Susceptibility Study (NAVRESS). J Antimicrob Chemother 52 (2003) 382-388
20. Lai K.K. Treatment of vancomycin-resistant Enterococcus faecium infections. Arch Intern Med 156 (1996) 2579-2584
21. Astal Z. Susceptibility patterns in Pseudomonas aeruginosa causing nosocomial infections. J Chemother 16 (2004) 264-268
22. Cunha B.A. Pseudomonas aeruginosa: resistance and therapy. Semin Respir Infect 17 (2002) 231-239
23. Friedland I., Gallagher G., King T., et al. Antimicrobial susceptibility patterns in Pseudomonas aeruginosa: data from a multicenter Intensive Care Surveillance Study (ISS) in the United States. J Chemother 16 (2004) 437-441
24. Karlowsky J.A., Draghi D.C., Jones M.E., et al. Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001. Antimicrob Agents Chemother 47 (2003) 1681-1688
25. Karakoc B., and Gerceker A.A. In-vitro activities of various antibiotics, alone and in combination with amikacin against Pseudomonas aeruginosa. Int J Antimicrob Agents 18 (2001) 567-570
26. Giamarellou-Bourboulis E.J., Kentepozidis N., Antonopoulos A., et al. Postantibiotic effect of antimicrobial combinations on multidrug-resistant Pseudomonas aeruginosa. Diagn Microbiol Infect Dis 51 (2005) 113-117
27. Savov E., Chankova D., Vatcheva R., et al. In vitro investigation of the susceptibility of Acinetobacter baumannii strains isolated from clinical specimens to ampicillin/sulbactam alone and in combination with amikacin. Int J Antimicrob Agents 20 (2002) 390-392
28. Corpus K.A., Weber K.B., and Zimmerman C.R. Intrathecal amikacin for the treatment of pseudomonal meningitis. Ann Pharmacother 38 (2004) 992-995
29. Fulnecky E.J., Wright D., Scheld M., et al. Amikacin and colistin for treatment of Acinetobacter baumannii meningitis. J Infect 51 (2005) e249-e251
30. Stein A., and Raoult D. Colistin: an antimicrobial for the 21st century?. Clin Infect Dis 35 (2002) 901-902
31. Berlana D., Llop J.M., Fort E., et al. Use of colistin is the treatment of multidrug resistant gram-negative infections. Am J Health Syst Pharm 62 (2005) 39-47
32. Falagas M.E., and Kasiakou S.K. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 40 (2005) 1333-1341
33. Levin A.S., Barone A.A., Penco J., et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 28 (1999) 1008-1011
34. Linden P.K., Kusne S., Coley K., et al. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin Infect Dis 37 (2003) 154-160
35. Markou N., Apostolakos H., Koumoudiou C., et al. Intravenous colistin in the treatment of sepsis from multidrug-resistant gram-negative bacilli in critically ill patients. Crit Care 7 (2003) 78-83
36. Michalopoulos A.S., Tsiodras S., Relios K., et al. Colistin treatment in patients with ICU-acquired infections caused by multiresistant gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect 11 (2005) 115-119
37. Michalopoulos A.S., Kasiakou S.K., Evangelos S., et al. Cure of multidrug-resistant Acinetobacter baumannii bacteraemia with continuous intravenous infusion of colistin. Clin Microbiol Infect 11 (2005) 119-121
38. Obritsch M.D., Fish D.N., MacLaren R., et al. Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options. Pharmacotherapy 25 (2005) 1353-1364
39. Murray C.K., and Hospenthal D.R. Treatment of multidrug resistant Acinetobacter. Curr Opin in Infectious Disease 18 (2005) 502-506
40. Reina R., Estenssoro E., Saenz G., et al. Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study. Intensive Care Med 31 (2005) 1058-1065
41. Horton J., and Pankey G.A. Polymyxin B, colistin, and sodium colistimethate. Med Clin North Am 66 (1982) 135-142
42. Lee S.Y., Kuti J.L., and Nicolau D.P. Polymyxins: older antibiotics for a new threat. Conn Med 70 (2006) 25-28
43. Menzies D., Minnaganti V.R., and Cunha B.A. Polymyxin B. Antibiotics for Clinicians 4 (2000) 33-40
44. Hermsen E.D., Sullivan C.J., and Rotschafer J.C. Polymyxins: pharmacology, pharmacokinetics, pharmacodynamics, and clinical applications. Infect Dis Clin North Am 17 (2003) 545-562
45. Tam V.H., Schilling A.N., Vo G., et al. Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrob Agents Chemother 49 (2005) 3624-3630
46. Sueke H., March H., and Dhital A. Using intrathecal colistin for multidrug resistant shunt infection. Br J Neurosurg 19 (2005) 51-52
47. Gump W.C., and Walsh J.W. Intrathecal colistin for treatment of highly resistant Pseudomonas ventriculitis. Case report and review of the literature. J Neurosurg 102 (2005) 915-917
48. Segal-Maurer S., Mariano N., Qavi A., et al. Successful treatment of ceftazidime-resistant Klebsiella pneumoniae ventriculitis with intravenous meropenem and intraventricular polymyxin B. Case report and review. Clin Infect Dis 28 (1999) 1134-1138
49. Katragkou A., and Roilides E. Successful treatment of multidrug-resistant Acinetobacter baumannii central nervous system infections with colistin. J Clin Microbiol 43 (2005) 4916-4917
50. Quinn A.L., Parada J.P., Belmares J., et al. Intrathecal colistin and sterilization of resistant Pseudomonas aeruginosa shunt infection. Ann Pharmacother 39 (2005) 949-952
51. Jimenez-Mejias M.E., Pichardo-Guerrero C., Marque-Rivas F.J., et al. Cerebrospinal fluid penetration and pharmacokinetic/pharmacodynamic parameters of intravenously administered colistin in a case of multidrug-resistant Acinetobacter baumannii meningitis. Eur J Clin Microbiol Infect Dis 21 (2002) 212-214
52. Parchuri S., Mohan S., Young S., et al. Chronic ambulatory peritoneal dialysis associated peritonitis ESBL-producing Klebsiella pneumoniae successfully treated with polymyxin B. Heart Lung 34 (2005) 360-363
53. In: Kucers A., Crowe S.M., Grayson M.L., et al. (Eds). The use of antibiotics. A clinical review of antibacterial, antifungal and antiviral drugs. 5th edition (1997), Butterworth-Heinemann, Oxford (UK) 667-675
54. Li H., Turnidge J., Milne R., et al. In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 45 (2001) 781-785
55. Kasiakou S.K., Michalopoulos A., Soteriades E.S., et al. Combination therapy with intravenous colistin for management of infections due to multidrug-resistant gram-negative bacteria in patients without cystic fibrosis. Antimicrob Agents Chemother 49 (2005) 3136-3146
56. Kasiakou S.K., Fragoulis K., Tzagarakis G., et al. Cure of multidrug-resistant Acinetobacter baumannii fixation device-related orthopedic infections in two patients with intravenous colistin. Microb Drug Resist 11 (2005) 287-289
57. Garnacho-Montero J., Ortiz-Leyba C., Jimenez-Jimenez F.J., et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 36 (2003) 1111-1118
58. Petrosillo N., Chinello P., Proietti M.F., et al. Combined colistin and rifampin therapy for carbapenem-resistant Acinetobacter baumannii infections: clinical outcome and adverse events. Clin Microbiol Infect 11 (2005) 682-683
59. Rynn C., Wooton M., Bowker K.E., et al. In vitro assessment of colistin's antipseudomonal antimicrobial interactions with other antibiotics. Clin Microbiol Infect 5 (1999) 32-36
60. Morrison D.C., and Jacobs D.M. Inhibition of lipopolysaccharide-initiated activation of serum complement by polymyxin B. Infect Immun 13 (1976) 298-301
61. Giamarellos-Bourboulis E.J., Xirouchaki E., and Giamarellou H. Interactions of colistin and rifampin on multidrug-resistant Acinetobacter-baumannii. Diagn Microbiol Infect Dis 40 (2001) 117-120
62. Solera J., Geijo P., Largo J., et al. A randomized, double-blind study to assess the optimal duration of doxycycline treatment for human brucellosis. Clin Infect Dis 39 (2004) 1776-1782
63. Pappas G., Akritidis N., Bosilkovski M., et al. Brucellosis. N Engl J Med 352 (2005) 2325-2336
64. Bhattacharya S.K. An evaluation of current cholera treatment. Expert Opin Pharmacother 4 (2003) 141-146
65. Chaowagul W., Chierakul W., Simpson A.J., et al. Open label randomized trial of oral trimethoprim-sulfamethoxazole, doxycycline, and chloramphenicol compared with trimethoprim-sulfamethoxazole and doxycycline for maintenance therapy of melioidosis. Antimicrob Agents Chemother 49 (2005) 4020-4025
66. Rolain J.M., Maurin M., Mallet M.N., et al. Culture and antibiotic susceptibility of Bartonella quintana in human erythrocytes. Antimicrob Agents Chemother 47 (2003) 614-619
67. Perez-Castrillon J.L., Bachiller-Luque P., Martin-Luquero M., et al. Tularemia epidemic in northwestern Spain: clinical description and therapeutic response. Clin Infect Dis 33 (2001) 573-576
68. Rolain J.M., Boulos A., Mallet M.N., et al. Correlation between ratio of serum doxycycline concentration to MIC and rapid decline of antibody levels during treatment of Q fever endocarditis. Antimicrob Agents Chemother 49 (2005) 2673-2676
69. Rolain J.M., Mallet M.N., and Raoult D. Correlation between serum doxycycline concentrations and serologic evolution in patients with Coxiella burnetii endocarditis. J Infect Dis 188 (2003) 1322-1325
70. Calza L., Attard L., Manfredi R., et al. Doxycycline and chloroquine as treatment for chronic Q fever endocarditis. J Infect 45 (2002) 127-129
71. Bryskier A. Bacillus anthracis and antibacterial agents. Clin Microbiol Infect 8 (2002) 467-478
72. Hernandez E., Girardet M., Ramisse F., et al. Antibiotic susceptibilities of 94 isolates of Yersinia pestis to 24 antimicrobial agents. J Antimicrob Chemother 52 (2003) 1029-1031
73. Boulos A., Rolain J.M., and Raoult D. Antibiotic susceptibility of Tropheryma whippleii in MRC5 cells. Antimicrob Agents Chemother 48 (2004) 747-752
74. Newton P.N., Chaulet J.F., Brockman A., et al. Pharmacokinetics of oral doxycycline during combination treatment of severe falciparum malaria. Antimicrob Agents Chemother 49 (2005) 1622-1625
75. Taylor W.R., Widjaja H., Richie T.L., et al. Chloroquine/doxycycline combination versus chloroquine alone, and doxycycline alone for the treatment of Plasmodium falciparum and Plasmodium vivax malaria in northeastern Irian Jaya, Indonesia. Am J Trop Med Hyg 64 (2001) 223-228
76. Hoerauf A., Mand S., Adjei O., et al. Depletion of wolbachia endobacteria in Onchocerca volvulus by doxycycline and microfilaridermia after ivermectin treatment. Lancet 357 (2001) 1415-1416
77. Hoerauf A., Mand S., Volkmann L., et al. Doxycycline in the treatment of human onchocerciasis: kinetics of Wolbachia endobacteria reduction and of inhibition of embryogenesis in female Onchocerca worms. Microbes Infect 5 (2003) 261-273
78. Hoerauf A., Adjei O., and Buttner D.W. Antibiotics for the treatment of onchocerciasis and other filarial infections. Curr Opin Investig Drugs 3 (2002) 533-537
79. Stolk W.A., de Vlas S.J., and Habbema J.D. Anti-Wolbachia treatment for lymphatic filariasis. Lancet 365 (2005) 2067-2068
80. Taylor M.J., Makunde W.H., McGarry H.F., et al. Macrofilaricidal activity after doxycycline treatment of Wuchereria bancrofti: a double-blind, randomized placebo-controlled trial. Lancet 365 (2005) 2116-2121
81. Klein N.C., and Cunha B.A. Tetracyclines. Med Clin North Am 79 (1995) 789-801
82. Shea K.W., Ueno Y., Abumustafa F., et al. Doxycycline activity against Streptococcus pneumoniae. Chest 107 (1995) 1775-1776
83. Lederman E.R., Gleeson T.D., Driscoll T., et al. Doxycycline sensitivity of S. pneumoniae isolates. Clin Infect Dis 36 (2003) 1091
84. Johnson J.R. Doxycycline for treatment of community-acquired pneumonia. Clin Infect Dis 35 (2002) 632-633
85. Jones R.N., Sader H.S., and Fritsche T.R. Doxycycline use for community-acquired pneumonia: contemporary in vitro spectrum of activity against Streptococcus pneumoniae (1999-2002). Diagn Microbiol Infect Dis 49 (2004) 147-149
86. Cunha B.A. Doxycycline for community-acquired pneumonia. Clin Infect Dis 37 (2003) 870
87. Cunha B.A. Empiric therapy of community-acquired pneumonia: guidelines for the perplexed?. Chest 125 (2004) 1913-1919
88. Cunha B.A. Doxycycline. Antibiotics for Clinicians 3 (1999) 21-33
89. Cunha B.A. Doxycycline re-visited. Arch Intern Med 159 (1999) 1006-1007
90. Cunha B.A., Domenico P.D., and Cunha C.B. Pharmacodynamics of doxycycline. Clin Microbiol Infect Dis 6 (2000) 270-273
91. Borg R., Dotevall L., Hagberg L., et al. Intravenous ceftriaxone compared with oral doxycycline for the treatment of Lyme neuroborreliosis. Scand J Infect Dis 37 (2005) 449-454
92. Jonas M., and Cunha B.A. Minocycline. Ther Drug Monit 4 (1982) 137-145
93. Yuk J.H., Dignani M.C., Harris R.L., et al. Minocycline as an alternative antistaphylococcal agent. Rev Infect Dis 13 (1991) 1023
94. Clumeck N., Marcelis L., Amiri-Lamraski M.H., et al. Treatment of severe staphylococcal infections with rifampin-minocycline association. J Antimicrob Chemother 13 (1984) 71-72
95. Lewis S., and Lewis B. Minocycline therapy of resistant Staphylococcus aureus infections. Infect Control Hosp Epidemiol 14 (1993) 423
96. Minuth J.N., Holmes T.M., and Mushen D.M. Activity of tetracycline, doxycycline and minocycline against methicillin-susceptible and resistant staphylococci. Antimicrob Agents Chemother 6 (1974) 411-414
97. Qadri S.M., Halim M., Ueno Y., et al. Susceptibility of methicillin-resistant Staphylococcus aureus to minocycline and other antimicrobials. Chemotherapy 40 (1994) 26
98. Cunha B.A. Methicillin-resistant Staphylococcus aureus: clinical manifestations and antimicrobial therapy. Clin Microbiol Infect 11 Suppl 4 (2005) 33-42
99. Yu W.-L., Wang D.-Y., Lin C.-W., et al. Endemic Burkholderia cepacia bacteraemia: clinical features and antimicrobial susceptibilities of isolates. Scand J Infect Dis 31 (1999) 293-298
100. Thibault F.M., Hernandez E., Vidal D.R., et al. Antibiotic susceptibilities of 65 isolates of Burkholderia pseudomallei and Burkholderia mallei to 35 antimicrobial agents. J Antimicrob Chemother 54 (2004) 1134-1138
101. Valdezate S., Vindel A., Loza E., et al. Antimicrobial susceptibilities of unique Stenotrophomonas maltophilia clinical strains. Antimicrob Agents Chemother 45 (2001) 1581-1584
102. Wood G.C., Hanes S.D., Boucher B.A., et al. Tetracyclines for treating multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia. Intensive Care Med 29 (2003) 2072-2076
103. Cunha B.A. Minocycline vs. doxycycline for the antimicrobial therapy of Lyme neuroborreliosis. Clin Infect Dis 30 (2000) 237-238
104. Lawler M.T., Sullivan M.C., Levitz R.E., et al. Treatment of prosthetic valve endocarditis due to methicillin-resistant Staphylococcus aureus with minocycline. J Infect Dis 161 (1990) 812-814